Settled, neither admitted nor denied CA NYSE

Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing

Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.

CASE PROFILE & BENCHMARKS
  • Target Issuer: Valeant Pharmaceuticals International, Inc. (CA).
  • Fraud Period: January 1, 2015 to December 31, 2017.
  • Reported Overstatement: $58.0M.
  • Total Fines & Penalties: $45.0M.
  • Maximum Incarceration: No prison sentence.
  • Independent Auditor: PricewaterhouseCoopers LLP.
  • Primary Schemes: channel stuffing.
  • Enforcement Status: SETTLED (neither admit nor deny).
OVERSTATEMENT $58.0M USD reported
TOTAL PENALTIES $45.0M Civil & disgorgement
PRISON TIME None No prison sentence
FIRST ACTION September 20, 2017 Initial proceeding
DETECTION METHOD Regulatory Enforcement & Forensic Audit Discovery source
PRIMARY REGULATOR U.S. Securities and Exchange Commission CA

FORENSIC ACCOUNTING AUTOPSY & MECHANICS

HOW IT WAS DONE
Forensic Aspect Regulatory Record & Ledger Mechanics
Accounting Mechanics Without admitting or denying the findings, the respondents consented to orders establishing that The company manipulated its accounting records by executing schemes under channel-stuffing. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.
Evidentiary Finding Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.
Mechanism Definition Shipping excessive quantities of inventory to distributors or resellers ahead of real demand to prematurely recognize revenue.
Affected Accounts Accounts Receivable (Asset) • Revenue (Income Statement) • Cost of Goods Sold (Income Statement) • Inventory (Asset)
Issuer Corporate Context Specialty pharmaceutical roll-up that used undisclosed captive specialty pharmacy Philidor Rx Services to stuff channels and accelerate revenues.
Independent Auditor PricewaterhouseCoopers LLP : Big Four accounting network sanctioned for audit failures in Satyam, Colonial Bank, Evergrande, and independence violations.
Primary Discovery Method Regulatory Enforcement & Forensic Audit

ILLUSTRATIVE GENERAL LEDGER MECHANICS (CHANNEL STUFFING)

IMPROPER VS. GAAP/IFRS TREATMENT
Improper Booked Entry Proper GAAP / IFRS Treatment Accounting Distortion & Mechanism
DR: Accounts Receivable: $10,000,000
CR: Sales Revenue: $10,000,000
DR: Finished Goods Inventory (remains on balance sheet): $6,000,000
CR: No revenue or AR recognized until legitimate delivery and demand criteria met
Issuer books large sales at quarter end by inducing distributors to take unneeded stock under deep discounts, secret return privileges, or extended payment terms.

FINANCIAL STATEMENT & RATIO DISTORTIONS

QUANTITATIVE SCREENING SIGNALS
Financial Metric / Ratio Distortion Direction Forensic Explanation
Days Sales Outstanding (DSO) Increases sharply Receivables surge because distributors cannot or do not pay for inventory they cannot sell.
Receivables to Revenue Ratio Increases Accounts receivable expands far faster than cash collections.
Gross Margin Unstable or declines next period Concessions, return allowances, or steep price cuts eventually compress margins.
Taxonomy Applicable Scheme Classifications
Correlated Schemes

CHARGED RESPONDENTS & OUTCOMES

1 NAMED PARTIES
Respondent Role Disposition & Judicial Outcome Prison Civil Penalty O&D Bar
Valeant Pharmaceuticals International, Inc. ISSUER Enforcement order and financial sanctions imposed. None $45.0M No

RED FLAGS OBSERVED PRIOR TO DISCOVERY

1 EARLY WARNING INDICATORS
Red Flag Indicator Period Observed Observed Forensic Anomaly Diagnostic View
CASH FLOW TO NET INCOME DIVERGENCE 2015 Operating cash flow severely diverged from reported earnings Inspect Metric →

ENFORCEMENT ACTIONS & PRIMARY DOCKETS

PRIMARY SOURCE CITATIONS
Filing Date Type & Docket ID Enforcement Order & Regulatory Findings Disposition Primary Record
September 20, 2017
foreign regulator
ENF-2015-valeant
Enforcement Action: Valeant Pharmaceuticals: Undisclosed Captive Pharmacy Philidor and Channel Stuffing
Used secret captive specialty pharmacy Philidor to prematurely recognize revenue and stuff distribution channels.
Securities & Corporate Law Compliance
neither admit nor deny Docket Record ↗

TIMELINE OF EVENTS

2 CHRONOLOGICAL MILESTONES
Date Event Category Chronological Forensic Milestone
June 1, 2015 MISSTATEMENT Material accounting irregularities commenced.
September 20, 2017 ENFORCEMENT Regulators commenced formal proceedings.